GRAIL FDA Panel Review Set for Galleri Cancer Blood Test

What Happened

GRAIL Inc. announced that the U.S. Food and Drug Administration has scheduled an advisory committee meeting in September to evaluate the company's Premarket Approval application for the Galleri multi-cancer detection blood test. The review marks a significant regulatory milestone for a test designed to screen for multiple cancer types from a single blood draw.

Background

GRAIL, listed on the Nasdaq exchange under the ticker GRAL, developed the Galleri test as a multi-cancer early detection screening tool. The test works by analyzing cell-free DNA fragments circulating in the bloodstream, a method known as liquid biopsy, to identify signals associated with more than 50 types of cancer. Multi-cancer early detection tests represent a category distinct from single-cancer screening tools such as mammograms or colonoscopies, which target one cancer type at a time.

The Premarket Approval pathway is the FDA's most rigorous review process for medical devices and diagnostic tests. An advisory committee convening to examine a PMA application means the agency has advanced the submission to a stage at which independent scientific experts will formally assess the clinical evidence before the FDA makes a final determination.

GRAIL has been among the most closely watched companies in the liquid biopsy space. The company was previously acquired by Illumina, a genomic sequencing firm, before regulators in the United States and Europe raised antitrust concerns. GRAIL subsequently returned to independent public company status.

The Galleri Test

Galleri is designed for use in adults at higher risk for cancer, typically those aged 50 and older, as a complement to existing single-cancer screening protocols rather than a replacement. The test produces a result indicating whether a cancer signal has been detected and, if so, identifies the tissue of origin to help direct follow-up diagnostic procedures.

Clinical study data submitted to the FDA as part of the PMA application covers the test's performance characteristics, including its sensitivity in detecting cancer signals and its specificity in avoiding false positives. The advisory committee will examine that data as part of its deliberations.

The Galleri test has been available in the United States on a limited basis under a laboratory-developed test framework, which does not require FDA approval but does not carry the agency's formal authorization. Full PMA approval would allow broader commercial deployment and reimbursement consideration by insurance providers.

Regulatory Context

The FDA's advisory committee process involves a panel of outside experts, typically oncologists, statisticians, patient advocates, and other relevant specialists, who review submitted evidence and vote on questions posed by the agency. The committee's recommendations are not binding, but the FDA follows them in the large majority of cases.

A September meeting date means the public review of clinical evidence for Galleri is expected to occur within weeks. The FDA typically issues a final decision on a PMA application within several months of an advisory committee meeting, though timelines can vary.

The broader multi-cancer early detection field has attracted substantial investment and regulatory attention. Several competing tests are in various stages of clinical development or regulatory review, including products from Exact Sciences and other diagnostics companies. Payers, including the Centers for Medicare and Medicaid Services, have been evaluating coverage frameworks for this category of test as clinical data continues to accumulate.

What Happens Next

The FDA advisory committee meeting to review GRAIL's PMA application for the Galleri test is scheduled for September, after which the agency will proceed toward a final regulatory decision.